Who Owns Legend Biotech Company?

Legend Biotech Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Legend Biotech?

Understanding the ownership of a biotechnology firm like Legend Biotech is key to grasping its strategic direction and market impact. Legend Biotech, a global player in cell therapy, was established in 2014 as a subsidiary of GenScript Biotech Corporation.

Following its IPO in June 2020, Legend Biotech's ownership structure broadened, injecting vital capital for its innovative cell therapy research, particularly its CAR-T therapies for blood cancers.

The company's lead product, Carvykti, received U.S. FDA approval in February 2022, a significant step in its market presence. This analysis explores the evolving ownership of Legend Biotech, from its parent company's initial stake to the influence of institutional and public shareholders, especially considering developments in 2024-2025.

The ownership of Legend Biotech is a mix of its founding entity, institutional investors, and public shareholders. GenScript Biotech Corporation, its parent company, initially held a significant stake. Following the company's 2020 IPO, a portion of shares became available to the public, leading to a diversified shareholder base. Institutional investors, such as mutual funds and hedge funds, also play a crucial role, often holding substantial blocks of shares. For a deeper dive into the company's operational environment, consider the Legend Biotech PESTEL Analysis.

The origins of Legend Biotech in 2014 are closely tied to its parent entity, GenScript Biotech Corporation. While specific details on individual founders and their initial equity stakes in Legend Biotech are not widely publicized, GenScript played a pivotal role in its early development and funding. Frank Fan is recognized as a founder of Legend Biotech, which was established in Nanjing, China.

GenScript's Foundational Role

GenScript Biotech Corporation provided the initial capital and scientific expertise for Legend Biotech's establishment. This strategic investment was crucial for the company's entry into the cell therapy sector.

Early Operational Structure

Operating initially as the 'Legend Project,' the company received comprehensive support from GenScript. This included funding for research and development and access to proprietary technology platforms.

Parent Company Ownership

GenScript held a significant ownership stake in Legend Biotech before its spin-off and public listing. Early agreements focused on resource allocation and intellectual property between the two entities.

Founder Recognition

Frank Fan is identified as a founder of Legend Biotech. His vision was instrumental in the company's inception and early strategic direction.

Absence of Early Disputes

During its formative years, there were no publicly reported ownership disputes or buyouts. Legend Biotech functioned as an integral part of GenScript's corporate structure.

Strategic Incubation

The company benefited from GenScript's incubation, which provided essential management support. This allowed Legend Biotech to focus on its pioneering work in cell therapy.

The strategic vision for Legend Biotech was an extension of GenScript's broader strategic initiatives into innovative therapeutic areas. During its initial phase, the company was known as the 'Legend Project,' and it thrived under GenScript's comprehensive support. This backing included crucial funding for research and development, access to GenScript's proprietary technology platforms, and essential management guidance. This incubation period meant that GenScript maintained a substantial ownership stake prior to Legend Biotech's eventual spin-off and subsequent public listing. The early arrangements were primarily concerned with the distribution of resources and intellectual property between the parent company and its developing subsidiary. As detailed in a Brief History of Legend Biotech, there were no public reports of ownership disputes or buyouts during this initial period, as Legend Biotech operated as a core component of GenScript's larger corporate framework, with its founding team's aspirations directly supported by GenScript's strategic financial commitment.

Key Aspects of Early Ownership

Understanding the early ownership structure is key to grasping Legend Biotech's trajectory. GenScript's role as the Legend Biotech parent company was foundational.

• GenScript Biotech Corporation provided initial capital and infrastructure.
• Frank Fan is a recognized founder of Legend Biotech.
• Early operations were supported by GenScript's R&D funding and technology platforms.
• GenScript held a substantial ownership stake before the company's public listing.

Legend Biotech SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Legend Biotech has evolved significantly, particularly following its Initial Public Offering (IPO) on June 5, 2020. This event transformed it from a subsidiary into a publicly traded entity, broadening its shareholder base.

GenScript Biotech Corporation was a significant shareholder, holding approximately 30.5% of the total ordinary shares as of March 31, 2024. However, a pivotal change occurred on October 18, 2024, when Legend Biotech rescinded its discretionary proxy. This action effectively removed GenScript's control over more than 50% of the voting rights, realigning voting power with direct equity ownership and upholding the one-share-one-vote principle. This shift means GenScript is no longer a majority shareholder. Institutional investors now represent a substantial portion of Legend Biotech's ownership. As of June 30, 2025, FMR LLC (Fidelity) was a leading institutional holder with 25,670,311 shares. Other key institutional investors include Westfield Capital Management Co Lp (6,472,547 shares), Blackrock, Inc. (4,248,568 shares), and Deerfield Management Company, L.P. (2,962,338 shares). Earlier data from March 31, 2024, showed The Vanguard Group holding 9.07%, BlackRock Inc. holding 6.13%, and State Street Corp holding 3.78%. While Johnson & Johnson (Janssen Biotech, Inc.) is a vital strategic partner for Carvykti, their role is primarily through a collaboration agreement, not direct equity ownership, though Johnson & Johnson Innovation - JJDC, Inc. was an early investor.

Key Institutional Investors in Legend Biotech

Institutional investors play a crucial role in Legend Biotech's shareholder landscape, contributing to market liquidity and corporate governance.

• FMR LLC (Fidelity) is a major holder as of June 30, 2025.
• Westfield Capital Management Co Lp also holds a significant number of shares.
• Blackrock, Inc. and The Vanguard Group are among the top institutional investors.
• The company's ownership structure reflects a blend of its historical ties and broad public market participation.
• Understanding these holdings is key to grasping the Marketing Strategy of Legend Biotech.

Legend Biotech PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The board of directors for Legend Biotech is structured to ensure a comprehensive oversight of the company's operations, incorporating key figures from its major stakeholders and independent experts. This composition aims to balance strategic direction with robust corporate governance, reflecting the company's commitment to transparency and shareholder interests.

Legend Biotech operates under a voting structure where ordinary shares, represented by American Depositary Shares (ADSs) on Nasdaq, adhere to a one-share-one-vote principle. This system ensures that voting power is directly tied to share ownership, providing a clear link between investment and influence. A significant governance change occurred in October 2024 when the company eliminated its discretionary proxy. This move removed GenScript Biotech Corporation's ability to cast votes on behalf of shareholders who had not provided specific voting instructions. The intention behind this decision was to ensure that shareholder votes solely determine outcomes, thereby preventing GenScript from unilaterally dictating the company's financial and operational policies, despite its substantial equity stake. This action reinforces the commitment to independent shareholder decision-making and is a key aspect of the Target Market of Legend Biotech.

Key Governance Developments

Legend Biotech has implemented changes to enhance shareholder voting power and corporate governance.

• The board includes representatives from major shareholders and independent directors.
• Dr. Frank Zhang serves as Chairman, with Dr. Ying Huang as CEO.
• Peter Salovey was appointed Lead Independent Director in June 2025.
• Discretionary proxy was removed in October 2024, strengthening shareholder voting rights.

Legend Biotech Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Legend Biotech's ownership landscape has evolved significantly over the past few years, marked by shifts in control and increasing institutional interest. A key development was the removal of GenScript Biotech Corporation's discretionary proxy in October 2024, which altered the voting power dynamics despite GenScript's substantial shareholding.

The company's ownership structure reflects a growing trend in the biotechnology sector, with institutional investors increasing their stakes. This surge in confidence is largely attributed to the success of its flagship product, Carvykti. As of June 30, 2025, FMR LLC (Fidelity) notably boosted its holdings by 94.41%, acquiring 25,670,311 shares and becoming a prominent institutional investor. Other significant institutional shareholders as of the same date include Westfield Capital Management Co Lp, Blackrock, Inc., and Deerfield Management Company, L.P., all of whom hold substantial positions, underscoring a broad market appetite for innovative therapies.

Institutional Investor Confidence

Increased institutional ownership, such as FMR LLC's substantial stake increase, signifies growing investor confidence in Legend Biotech's future growth and the commercial success of its key therapies.

Strategic Manufacturing Agreements

The Master Manufacturing and Supply Services Agreement with Novartis Pharmaceuticals Corporation and Janssen Pharmaceuticals Inc. enhances manufacturing capabilities for cilta-cel, ensuring supply chain robustness through December 31, 2029.

Corporate Governance Enhancements

The appointment of Peter Salovey as Lead Independent Director in June 2025 highlights the company's commitment to strong corporate governance and strategic oversight during its expansion phase.

Capital Raising and Share Structure

The company's proposed public offering of ADSs in December 2023 and a total of 367 million shares outstanding as of June 30, 2025, indicate active engagement in capital markets to fuel its growth and development initiatives.

Legend Biotech Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔